Terminated NA INTERVENTIONAL 2-arm NCT01410201

Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane (OZURDEX2)

Dexamethasone Intravitreal Implant After Vitrectomy for Idiopathic Epiretinal Membrane

Sponsor: Allergan

Conditions Epiretinal Membrane Macular Edema

Interventions Dexamethasone Intravitreal Implant

Updated 7 times since 2017 Last updated: Jul 26, 2016 Started: Aug 31, 2011 Primary completion: Jan 31, 2016 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

recruitment not met

Other terminated trials from Allergan

See all terminations from Allergan

This NA trial investigates Epiretinal Membrane and Macular Edema and is currently terminated or withdrawn. Allergan leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated NA
Sep 2024 — Sep 2025 [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2021 — Jul 2024 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated NA
Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan
Barnes Retina Institute

Data source: Barnes Retina Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chesterfield, United States
• St Louis, United States